A Phase II placebo-controlled study of FIN-403 for recurrent C. difficile infections.
Phase of Trial: Phase II
Latest Information Update: 02 Mar 2017
At a glance
- Drugs FIN 403 (Primary)
- Indications Clostridium infections
- Focus Therapeutic Use
- 02 Mar 2017 New trial record
- 23 Feb 2017 According to Finch Therapeutics media release, company planing to initiate this study in second half of 2017.